- Title
- KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC
- Creators
- Heather A WakeleeMoishe LibermanTerufumi KatoMasahiro TsuboiSe-Hoon LeeJie HeShugeng GaoKe-Neng ChenChristophe Alfons DoomsMargarita MajemEkkehard EigendorffGaston Lucas MartinengoOlivier BylickiDelvys Rodriguez-AbreuJamie E ChaftSilvia NovelloJing YangSteven M KellerAyman SamkariJonathan Spicer
- Publication Details
- JOURNAL OF CLINICAL ONCOLOGY, v 41(17_SUPPL), pLBA100
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Pediatrics
- Web of Science ID
- WOS:001182783300019
- Other Identifier
- 991021879415704721
Journal article
KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC
JOURNAL OF CLINICAL ONCOLOGY, v 41(17_SUPPL), pLBA100
10 Jun 2023
Featured in Collection : UN Sustainable Development Goals @ Drexel
Metrics
21 Record Views
Details
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Industry collaboration
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Oncology